Page last updated: 2024-11-08

salicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID439503
CHEMBL ID462997
CHEBI ID17814
SCHEMBL ID24936
MeSH IDM0047403

Synonyms (120)

Synonym
salicyl alcohol glucoside
nsc-5751
salicine
o-(hydroxymethyl)phenyl beta-d-glucopyranoside
saligenin beta-d-glucopyranoside
2-(hydroxymethyl)phenyl beta-d-glucopyranoside
2-(hydroxymethyl)phenyl-o-beta-d-glucopyranoside
2-(hydroxymethyl)phenyl-beta-d-glucopyranoside
d-(-)-salicin ,
CHEBI:17814 ,
DIVK1C_000030
KBIO1_000030
SDCCGMLS-0066698.P001 ,
SPECTRUM_001230
einecs 205-331-6
benzyl alcohol, o-hydroxy-, o-glucoside
beta-d-glucopyranoside, 2-(hydroxymethyl)phenyl
b-d-glucopyranoside, 2-(hydroxymethyl)phenyl
nsc 5751
saligenin-beta-d-glucopyranoside
alpha-hydroxy-o-tolyl beta-d-glucopyranoside
salicin (6ci,8ci)
ai3-19099
d-salicin
SPECTRUM5_000971
MEGXP0_000685
d(-)-salicin
138-52-3
2-(hydroxymethyl)-phenyl-beta-d-glucopyranoside
C01451
salicoside
salicin ,
d-(-)-salicin, >=99% (gc)
S0625_SIGMA ,
ACON1_000373
IDI1_000030
NCGC00142605-01 ,
KBIO3_002016
KBIOSS_001710
KBIOGR_001356
KBIO2_001710
KBIO2_004278
KBIO2_006846
SPECTRUM3_000948
SPBIO_000772
SPECTRUM2_000756
NINDS_000030
SPECTRUM4_001058
SPECTRUM1502255 ,
d-()-salicin
smr000112301
NCGC00142605-02
MLS001306490
MLS000563050
EAD32BE1-198E-432C-9F44-DC0DC9A3305B
HMS2092F14
BRD-K64614248-001-02-4
zinc03847505
2(hydroxymethyl)phenyl-beta-d-glucopyranoside
BMSE000315
HMS500B12
2-(hydroxymethyl)phenyl hexopyranoside
CHEMBL462997
salicinum
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol
S0003
HMS1921P08
AKOS004907439
salicin [usp]
unii-4649620tbz
4649620tbz ,
(2s,4s,5s,3r,6r)-6-(hydroxymethyl)-2-[2-(hydroxymethyl)phenoxy]-2h-3,4,5,6-tet rahydropyran-3,4,5-triol
nsc758201
pharmakon1600-01502255
nsc-758201
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(2-(hydroxymethyl)phenoxy)tetrahydro-2h-pyran-3,4,5-triol
sa0 ,
HMS2268J11
c13h18o7
CCG-40332
S2351
salicyl alcohol glucoside [who-dd]
salicinum [hpus]
salicin [inci]
salicin [mi]
d-salicin [usp-rs]
2-(hydroxymethyl)phenyl-.beta.-d-glucopyranoside
SCHEMBL24936
CS-8027
HY-N0149
AB00052296_07
mfcd00006590
d-(-)-salicin, analytical standard
d-(?)-salicin
AC-8042
NGFMICBWJRZIBI-UJPOAAIJSA-N
delta-salicin
saligenin-b-d-glucopyranoside
saligenin-beta-delta-glucopyranoside
sr-05000001594
SR-05000001594-1
SR-05000001594-2
saligenin glucoside
salicin, european pharmacopoeia (ep) reference standard
SBI-0051746.P002
NCGC00142605-04
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(2-(hydroxymethyl)-phenoxy)tetrahydro-2h-pyran-3,4,5-triol
d-salicin, united states pharmacopeia (usp) reference standard
SW219123-1
DTXSID10883326
Q419173
salicin (salicoside, salicine)
saligenin beta-delta-glucopyranoside
BRD-K64614248-001-06-5
HMS3884B15
2-(hydroxymethyl)phenyl-beta-d-glucopyranoside, salicoside, salicyl alcohol glucoside, saligenin beta-d-glucoside
d-()-salicin;salicoside
wurcs=2.0/1,1,0/[a2122h-1b_1-5_1*o(c^zc^zc^zc^zc^zc^e$3)/4co]/1/
GLXC-13826
gtpl12454

Research Excerpts

Overview

Beta-Salicin is a naturally occurring glycoside found in the bark of poplar and willow trees. It is known to exhibit anti-inflammation and other therapeutic activities.

ExcerptReferenceRelevance
"D(-)-Salicin is a traditional medicine which has been known to exhibit anti-inflammation and other therapeutic activities. "( D(-)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models.
Chi, G; Deng, Y; Feng, H; Li, Y; Lv, H; Qiu, J; Wu, Q, 2015
)
1.44
"Beta-Salicin is a naturally occurring glycoside found in the bark of poplar and willow trees. "( Enzymatic synthesis of two salicin analogues by reaction of salicyl alcohol with Bacillus macerans cyclomaltodextrin glucanyltransferase and Leuconostoc mesenteroides B-742CB dextransucrase.
Bruce Fulton, D; Robyt, JF; Yoon, SH, 2004
)
1.13

Effects

Salicin has been studied as a potent antiinflammatory agent. Salicin may have therapeutic value in ameliorating inflammation during colitis.

ExcerptReferenceRelevance
"Salicin has an anti-inflammatory effect, and it may have therapeutic value in ameliorating inflammation during colitis."( Effect of salicin on gut inflammation and on selected groups of gut microbiota in dextran sodium sulfate induced mouse model of colitis.
Kumari, R; Paul, J; Ranjha, R; Verma, N; Verma, R, 2014
)
2.25
"Salicin has an anti-inflammatory effect, and it may have therapeutic value in ameliorating inflammation during colitis."( Effect of salicin on gut inflammation and on selected groups of gut microbiota in dextran sodium sulfate induced mouse model of colitis.
Kumari, R; Paul, J; Ranjha, R; Verma, N; Verma, R, 2014
)
2.25
"Salicin has been studied as a potent antiinflammatory agent. "( Salicin, an extract from white willow bark, inhibits angiogenesis by blocking the ROS-ERK pathways.
Choi, JS; Jeong, JW; Kim, JE; Kim, KH; Kong, CS; Park, C, 2014
)
3.29

Treatment

Salicin ether treatment suppressed rosiglitazone induced expression of FAS, C/EBPα, aP2, and HMG-CoA genes. Treatment with salicin dimethyl ether led to a prominent reduction in Bcl-2 protein expression in TU686 and Tu212 cells at 72 h.

ExcerptReferenceRelevance
"Salicin ether treatment of the adipocytes effectively suppressed rosiglitazone induced expression of FAS, C/EBPα, aP2, and HMG-CoA genes."( Preventive effect of salicin ether against type-2 diabetes mellitus through targeting PPARγ-regulated gene expression.
Xiang, G; Yue, L; Zhang, J; Zhu, G, 2022
)
1.76
"Treatment with salicin dimethyl ether led to a prominent reduction in Bcl-2 protein expression in TU686 and Tu212 cells at 72 h."( Preparation and inhibitory effect of salicin dimethyl ether in Laryngeal cancer cells through the apoptosis activation.
Bai, Y; Dong, K; Kong, X; Li, D; Shen, Y; Wang, Y; Zhang, R, 2022
)
1.33

Toxicity

ExcerptReferenceRelevance
"Gene expression profiles of Sprague-Dawley (SD) rats treated with a standardized willow bark extract (WB), its salicin rich ethanol fraction (EtOH-FR) or the tricyclic antidepressant imipramine were evaluated for their potential to induce adverse events."( Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine.
Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H, 2012
)
0.59
"Gene expression profiles (Agilent Whole Genome Array, n=4/group) obtained from the peripheral blood of male SD rats treated with WB (STW 33-I), EtOH-FR (30 mg/kg bw) or imipramine (20 mg/kg bw) were analysed comparatively by the Ingenuity Systems Programme, which allows to conduct model calculations of thresholds for theoretical potential adverse events (AE)."( Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine.
Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H, 2012
)
0.38
" Those correspond to known potential adverse events."( Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine.
Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H, 2012
)
0.38
" Adverse effects appear to be minimal as compared to non-steroidal anti-inflammatory drugs including aspirin."( Efficacy and Safety of White Willow Bark (Salix alba) Extracts.
Shara, M; Stohs, SJ, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" Renal excretion rate, elimination half-life and total bioavailability of salicylates were calculated."( Pharmacokinetics of salicin after oral administration of a standardised willow bark extract.
Heide, L; Kötter, I; Schmid, B, 2001
)
0.63

Bioavailability

ExcerptReferenceRelevance
" After oral administration to rats it will be only poorly absorbed and mostly unchanged fecaly excreted."( [Biotransformation of phenolglycosides leiocarposide and salicin].
Bartoszek, M; Fötsch, G; Franke, P; Hiller, K; Pfeifer, S, 1989
)
0.52
" Renal excretion rate, elimination half-life and total bioavailability of salicylates were calculated."( Pharmacokinetics of salicin after oral administration of a standardised willow bark extract.
Heide, L; Kötter, I; Schmid, B, 2001
)
0.63
" Therefore, these salicin-α-D-glucosides should be applied by the injection route to achieve greater bioavailability than is possible by the oral route."( Application of amylomaltase for the synthesis of salicin-α-glucosides as efficient anticoagulant and anti-inflammatory agents.
Kaulpiboon, J; Rudeekulthamrong, P, 2016
)
1.02
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Maxillary taste neurons of the two strains had similar dose-response relationships for sucrose, inositol, and strychnine nitrate, but the deterrent cell of Sawa-J·lem showed a remarkably low sensitivity to salicin."( Genetic analysis of the electrophysiological response to salicin, a bitter substance, in a polyphagous strain of the silkworm Bombyx mori.
Asaoka, K; Iizuka, T; Mase, K; Okada, E; Sezutsu, H; Tamura, T, 2012
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
antipyreticA drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
non-narcotic analgesicA drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitorA compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aryl beta-D-glucoside
aromatic primary alcoholAny primary alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring.
benzyl alcoholsCompounds containing a phenylmethanol skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
salicin biosynthesis012

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.44670.004023.8416100.0000AID485290
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Taste receptor type 2 member 16Homo sapiens (human)EC50 (µMol)1,400.00000.00490.15500.2500AID1619458; AID1619466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 16Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
G protein-coupled receptor activityTaste receptor type 2 member 16Homo sapiens (human)
protein bindingTaste receptor type 2 member 16Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endoplasmic reticulumTaste receptor type 2 member 16Homo sapiens (human)
trans-Golgi networkTaste receptor type 2 member 16Homo sapiens (human)
plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
external side of plasma membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
membraneTaste receptor type 2 member 16Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID336921Antifungal activity against Microsporum canis at 500 ug/ml
AID378416Allergy preventing effect in hen egg lysosome-sensitized ddY mouse assessed as inhibition of blood flow decrease in tail artery at 20 mg/kg, po after 5 days relative to control2006Journal of natural products, Aug, Volume: 69, Issue:8
Allergy-preventive phenolic glycosides from Populus sieboldii.
AID336920Antiviral activity against Poliovirus infected in african green monkey Vero cells assessed as ratio of viral titer in absence to presence of compound at 25 ug/ml by 50% endpoint titration technique
AID336914Antiviral activity against Herpes simplex virus type 1 infected in african green monkey Vero cells assessed as ratio of viral titer in absence to presence of compound at 500 ug/ml by 50% endpoint titration technique
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID385238Inhibition of COX2 at 10 uM2008Journal of natural products, May, Volume: 71, Issue:5
Itosides J-N from Itoa orientalis and structure - anti-COX-2 activity relationship of phenolic glycosides.
AID378799ABTS radical scavenging activity assessed as Trolox equivalent antioxidant capacity index2006Journal of natural products, Sep, Volume: 69, Issue:9
Phenolic glycosides with antioxidant activity from the stem bark of Populus davidiana.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID336924Antifungal activity against Aspergillus niger at 500 ug/ml
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID336923Antifungal activity against Trichophyton rubrum at 500 ug/ml
AID336918Antiviral activity against Semliki forest virus infected in african green monkey Vero cells assessed as ratio of viral titer in absence to presence of compound at 500 ug/ml by 50% endpoint titration technique
AID336912Antiviral activity against Coxsackievirus infected in african green monkey Vero cells assessed as ratio of viral titer in absence to presence of compound at 500 ug/ml by 50% endpoint titration technique
AID336922Antifungal activity against Trichophyton mentagrophytes at 500 ug/ml
AID336915Antiviral activity against Measles virus infected in african green monkey Vero cells assessed as ratio of viral titer in absence to presence of compound at 500 ug/ml by 50% endpoint titration technique
AID1771669Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells at 10 uM measured after 2 hrs by ELISA relative to control2021Journal of natural products, 09-24, Volume: 84, Issue:9
Salicinoyl Quinic Acids and Their Prostaglandin E
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (248)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (10.08)18.7374
1990's20 (8.06)18.2507
2000's81 (32.66)29.6817
2010's100 (40.32)24.3611
2020's22 (8.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.34 (24.57)
Research Supply Index5.58 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index92.70 (26.88)
Search Engine Supply Index2.10 (0.95)

This Compound (54.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (2.33%)5.53%
Reviews11 (4.28%)6.00%
Case Studies5 (1.95%)4.05%
Observational0 (0.00%)0.25%
Other235 (91.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]